Syntal Capital Partners’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Syntal Capital Partners’s Portfolio IHE Stock Details IHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-53,241	Closed	-$2.48M	–	148
2019 Q3	$2.48M	Hold	53,241	–	–	0.64%	31
2019 Q2	$2.68M	Buy	+53,241	New	+$2.63M	0.58%	34
2014 Q2	–	Sell	-53,241	Closed	-$2.25K	–	233
2014 Q1	$2.25K	Buy	+53,241	New	+$2.23M	1.32%	14

Other funds holding IHE

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Syntal Capital Partners's IHE Position: Q4 2019 in Review

Syntal Capital Partners sold out of iShares US Pharmaceuticals ETF (IHE) in Q4 2019, closing a stake of 53,241 shares — an estimated $2.48M sold.

Syntal Capital Partners first reported a position in IHE in Q1 2014 and held it in 3 quarters. The position peaked at $2.68M in Q2 2019. 95 funds tracked by Wall St. Rank hold IHE as of Q4 2019.

Syntal Capital Partners reported no remaining iShares US Pharmaceuticals ETF position as of Q4 2019 after selling out during the quarter.
Syntal Capital Partners sold 53,241 iShares US Pharmaceuticals ETF shares in Q4 2019, an estimated $2.48M.
Syntal Capital Partners first reported a position in iShares US Pharmaceuticals ETF in Q1 2014 and held it in 3 quarters.
Syntal Capital Partners's iShares US Pharmaceuticals ETF position peaked at $2.68M in Q2 2019.
95 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q4 2019.

Based on Syntal Capital Partners's 13F filing for Q4 2019, filed 10 Feb 2020.